Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Celebrates PC111 Breakthrough Following Prestigious Award

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a significant milestone in the development of PC111, a first-in-class anti-Fas Ligand monoclonal antibody, following Dr. Roberta Lotti of Pincell Srl receiving the 'Oscar of Italian Dermatology' from SIDeMaST. This accolade highlights the groundbreaking research published under the title 'Blocking soluble Fas Ligand ameliorates pemphigus', which demonstrates PC111's efficacy in preventing blister formation by inhibiting keratinocyte apoptosis in pemphigus vulgaris. Scinai, holding an option to acquire Pincell, is prioritizing PC111 as a lead asset, emphasizing its promise as a non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions. For further details, visit https://ibn.fm/51v14.